Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + MK-4830 + paclitaxel
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This drug is an experimental combination therapy for cancer composed of three agents: - **Pembrolizumab**, a humanized monoclonal antibody that inhibits the programmed death-1 (PD-1) receptor, thereby enhancing T-cell-mediated immune responses against tumor cells. - **MK-4830**, an investigational monoclonal antibody that targets the immunoregulatory receptor ILT4 (also known as LILRB2), which is involved in suppressing myeloid cell-mediated immune responses; blocking ILT4 is intended to diminish immune suppression in the tumor microenvironment and further enhance antitumor immunity. - **Paclitaxel**, a microtubule-stabilizing chemotherapy agent that disrupts cell division and causes cancer cell death. This combination is being investigated primarily for solid tumors, with clinical trials focusing on indications such as high-grade serous ovarian cancer and triple-negative breast cancer. The combination is designed to synergistically promote anti-tumor immune activity while directly killing tumor cells through chemotherapy[1][2][4].
- Other names
- pembrolizumab + MK-4830 + paclitaxel
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)MicrotubuleLILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2)
Beyond the preview
Go deeper on pembrolizumab + MK-4830 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + MK-4830 + paclitaxel.